First-Line Therapy in Ovarian Cancer Trials
- 1 April 2011
- journal article
- review article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 21 (4), 756-762
- https://doi.org/10.1097/igc.0b013e31821ce75d
Abstract
At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients. A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)? A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials? A3: Is the 2004 GCIG-recommended standard comparator arm still valid? A4: What is the role of modifying dose, schedule, and delivery of chemotherapy? A5: What role does surgery play today?Keywords
This publication has 23 references indexed in Scilit:
- Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology GroupJournal of Clinical Oncology, 2009
- Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group studyGynecologic Oncology, 2006
- A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a gynecologic oncology group studyGynecologic Oncology, 2003
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.Journal of Clinical Oncology, 1998
- Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II TrialGynecologic Oncology, 1998
- Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1998
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.Journal of Clinical Oncology, 1996
- A Phase II Trial of 5-Fluorouracil and High-Dose Leucovorin in Recurrent Epithelial Ovarian CarcinomaAmerican Journal of Clinical Oncology, 1995